Holen Sie sich die Stockscreener-App
93.97
2.50%
-2.41
Vorhandelsmarkt:
94.01
0.04
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$96.38
Offen:
$94.45
24-Stunden-Volumen:
1.17M
Relative Volume:
0.98
Marktkapitalisierung:
$10.48B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
44.51
EPS:
2.1112
Netto-Cashflow:
$492.45M
1W Leistung:
-6.96%
1M Leistung:
+1.15%
6M Leistung:
+1.34%
1J Leistung:
+3.95%
1-Tages-Spanne:
$93.83
$95.62
1-Wochen-Bereich:
$93.83
$103.00
52-Wochen-Spanne:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
93.97 | 10.75B | 2.90B | 239.11M | 492.45M | 2.1112 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake - AD HOC NEWS
FDA OKs Revvity’s Total Testosterone Assay - Medical Product Outsourcing
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity - Stock Titan
(RVTY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS - AD HOC NEWS
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay - The Globe and Mail
BofA Securities Maintains Revvity(RVTY.US) With Hold Rating - Moomoo
Is Revvity stock underperforming the S&P 500? - MSN
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says U - GuruFocus
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat - AD HOC NEWS
FDA Clears Revvity Total Testosterone Assay for Automated Testing - Clinical Lab Products
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution - Yahoo Finance
Revvity (RVTY) grows Q1 2026 sales to $711M while margins tighten - Stock Titan
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains - AD HOC NEWS
RVTY Technical Analysis | Trend, Signals & Chart Patterns | REVVITY INC (NYSE:RVTY) - ChartMill
Revvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (RVTY) director Alexis Michas receives stock awards and reports indirect holdings - Stock Titan
REVVITY (RVTY) director granted new restricted stock unit awards - Stock Titan
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants - Stock Titan
Revvity (RVTY) director Frank Witney granted restricted stock unit awards - Stock Titan
Director Samuel R. Chapin receives stock awards at REVVITY (RVTY) with RSUs vesting in 2027 - Stock Titan
Revvity (RVTY) director Michel Vounatsos receives new restricted stock units - Stock Titan
Revvity (RVTY) director Michelle McMurry-Heath granted new RSU awards - Stock Titan
Equity grants add 2,280 shares to Revvity (RVTY) director’s stake - Stock Titan
Revvity (RVTY) Q1 2026 Earnings Transcript - AOL.com
Revvity stock (US76155R1086): Q1 beat and analyst upgrade spark gains - AD HOC NEWS
Mitsubishi UFJ Asset Management Co. Ltd. Trims Stake in Revvity Inc. $RVTY - MarketBeat
Revvity (RVTY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Revvity earnings: What to look for from RVTY - MSN
Revvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestiture - MSN
Revvity Inc. stock (US76155R1086): Barclays lifts price target as Q1 beats estimates - AD HOC NEWS
Revvity, Inc. (NYSE:RVTY) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
Revvity, Inc. (NYSE:RVTY) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Revvity declares $0.07 dividend - MSN
RVTY Maintained by Barclays -- Price Target Raised to $105 - GuruFocus
Stifel Maintains Revvity(RVTY.US) With Hold Rating, Cuts Target Price to $100 - Moomoo
Revvity Is Maintained at Equal-Weight by Barclays - Moomoo
Revvity (RVTY) Net Margin Deterioration Tests Bullish Recovery Narratives Ahead Of Q1 2026 - Sahm
Is Revvity’s (RVTY) China Exit and EPS Reset Quietly Rewriting Its Portfolio Strategy? - Yahoo Finance
Goldman Sachs Maintains Revvity(RVTY.US) With Hold Rating, Cuts Target Price to $100 - Moomoo
RVTY Q1 2026 deep dive: Portfolio pruning and AI investments shape outlook - MSN
Barclays Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $105 - Moomoo
Revvity Q1 Adjusted Earnings, Revenue Rise - Moomoo
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):